AJMC » Biosimilars
4 FOLLOWERS
The American Journal of Managed Care is the leading peer-reviewed journal dedicated to issues in managed care. It distributes healthcare news to leading stakeholders across a variety of platforms. Its Evidence-Based series brings together stakeholder views from payers, providers, policymakers, and pharmaceutical leaders in oncology and diabetes management.
AJMC » Biosimilars
6d ago
Patients with radiographic axial spondyloarthritis (ax-SpA) and a high risk of radiographic progression had similar low progression on both secukinumab and an adalimumab biosimilar ..read more
AJMC » Biosimilars
6d ago
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab ..read more
AJMC » Biosimilars
2w ago
Biosimilars offer substantial promise for a new era of accessibility and affordability for patients and the broader health care industry, but better understanding of these products from payers and providers is necessary for biosimilars to reach their full potential in the US ..read more
AJMC » Biosimilars
2w ago
Wyost and Jubbonti were approved as interchangeable biosimilars for Xgeva and Prolia; however, there is no launch date yet pending litigation with the maker of the reference products ..read more
AJMC » Biosimilars
3M ago
The most popular content from our Asembia coverage largely covered biosimilars ..read more
AJMC » Biosimilars
3M ago
While the first ustekinumab biosimilar, Wezlana, was approved in October 2023, a settlement with Johnson & Johnson (J&J) will keep it off the market until 2025, preventing competition, and causing purchasers to pay substantially more for the agent ..read more
AJMC » Biosimilars
5M ago
Through interviews and contributed content, Strategic Alliance Partnerships provide insights into changes in health care delivery and medicine ..read more
AJMC » Biosimilars
6M ago
Bio-Thera Solutions’ Avzivi (bevacizumab-tnjn) has become the fifth biosimilar referencing Avastin (bevacizumab) to be approved in the United States ..read more
AJMC » Biosimilars
8M ago
In 2023, adalimumab biosimilars took center stage in the biosimilar space due to 8 long-anticipated products finally launching ..read more